We conclude that 5-HT1A receptor agonists offer a therapeutic option for retinal degenerations such as AMD, diabetic retinopathy or retinitis pigmentosa which involve oxidative stress and/or lipofuscin accumulation. This evidence concerns the gene HTR1A and age-related macular degeneration.